Dr. Dennis Slamon's honor in precision medicine masks the crushing reality of high drug costs and access inequality in modern healthcare.
Anthropic is pushing Claude into life sciences, but the real story isn't better diagnoses—it's who controls the new medical intelligence bottleneck.
The appointment at Health Data Research Service signals a massive power shift in UK medical innovation. Who truly controls your genome?
Vail Health's 'Healthspan' program promises longevity, but we analyze who really benefits from this hyper-personalized wellness trend.
BioRender's move to give AI a visual language for science is more than just better graphics; it's a power grab reshaping scientific communication and data ownership.
Congress debates technology lowering healthcare costs, but the real battle is over who controls the data and profits.
Guardant Health's strong Q3 performance masks a brutal reality: the race for **liquid biopsy** dominance is about to get bloodier, threatening current **healthcare technology** valuations.